Skip to main content

Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance.

Publication ,  Journal Article
Zhang, M; Fu, W; Prabhu, S; Moore, JC; Ko, J; Kim, JW; Druker, BJ; Trapp, V; Fruehauf, J; Gram, H; Fan, HY; Ong, ST
Published in: Mol Cell Biol
October 2008

Dysregulated mRNA translation is implicated in the pathogenesis of many human cancers including chronic myelogenous leukemia (CML). Because our prior work has specifically implicated translation initiation in CML, we tested compounds that could modulate translation initiation and polysomal mRNA assembly. Here, we evaluated the activity of one such compound, CGP57380, against CML cells and explored its mechanisms of action. First, using polysomal mRNA profiles, we found that imatinib and CGP57380 could independently, and cooperatively, impair polysomal mRNA loading. Imatinib and CGP57380 also synergistically inhibited the growth of Ba/F3-Bcr-Abl and K562 cells via impaired cell cycle entry and increased apoptosis. Mechanistically, CGP57380 inhibited efficient polysomal assembly via two processes. First, it enhanced imatinib-mediated inhibition of eukaryotic initiation factor 4F induction, and second, it independently impaired phosphorylation of ribosomal protein S6 on the preinitiation complex. We also identified multiple substrates of the mTOR, Rsk, and Mnk kinases as targets of CGP57380. Finally, we found a novel negative-feedback loop to the mitogen-activated protein kinase/Mnk pathway that is triggered by CGP57380 and demonstrated that an interruption of the loop further increased the activity of the combination against imatinib-sensitive and -resistant CML cells. Together, this work supports the inhibition of translation initiation as a therapeutic strategy for treating cancers fueled by dysregulated translation.

Duke Scholars

Published In

Mol Cell Biol

DOI

EISSN

1098-5549

Publication Date

October 2008

Volume

28

Issue

20

Start / End Page

6496 / 6509

Location

United States

Related Subject Headings

  • TOR Serine-Threonine Kinases
  • Substrate Specificity
  • Signal Transduction
  • Ribosomal Protein S6
  • RNA, Messenger
  • RNA Transport
  • RNA Caps
  • Pyrimidines
  • Purines
  • Protein Kinases
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Zhang, M., Fu, W., Prabhu, S., Moore, J. C., Ko, J., Kim, J. W., … Ong, S. T. (2008). Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance. Mol Cell Biol, 28(20), 6496–6509. https://doi.org/10.1128/MCB.00477-08
Zhang, Min, Wuxia Fu, Sharmila Prabhu, James C. Moore, Je Ko, Jung Woo Kim, Brian J. Druker, et al. “Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance.Mol Cell Biol 28, no. 20 (October 2008): 6496–6509. https://doi.org/10.1128/MCB.00477-08.
Zhang M, Fu W, Prabhu S, Moore JC, Ko J, Kim JW, et al. Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance. Mol Cell Biol. 2008 Oct;28(20):6496–509.
Zhang, Min, et al. “Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance.Mol Cell Biol, vol. 28, no. 20, Oct. 2008, pp. 6496–509. Pubmed, doi:10.1128/MCB.00477-08.
Zhang M, Fu W, Prabhu S, Moore JC, Ko J, Kim JW, Druker BJ, Trapp V, Fruehauf J, Gram H, Fan HY, Ong ST. Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance. Mol Cell Biol. 2008 Oct;28(20):6496–6509.

Published In

Mol Cell Biol

DOI

EISSN

1098-5549

Publication Date

October 2008

Volume

28

Issue

20

Start / End Page

6496 / 6509

Location

United States

Related Subject Headings

  • TOR Serine-Threonine Kinases
  • Substrate Specificity
  • Signal Transduction
  • Ribosomal Protein S6
  • RNA, Messenger
  • RNA Transport
  • RNA Caps
  • Pyrimidines
  • Purines
  • Protein Kinases